Targeting NF-κB and HIF-1 Pathways for the Treatment of Cancer: Part II
Abstract
Hypoxia that originates from disturbed growth of solid tumors initiates a cascade of intracellular events engaging hypoxia-inducible factors, HIF-1 and HIF-2. Overexpression of HIF has been confirmed in solid tumors and was unfortunately accompanied with chemo- and radioresistance observed in many patients. Multiple cellular pathways resulting in HIF activation could be successfully inhibited by use of different kinds of drugs (e.g. topotecan, heat shock protein 90 and mTOR inhibitors, YC-1, pleurotin or 2-methoxyestradiol), which are being subjected into intensive investigation in clinical trials.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Therapies designed to interfere with HIF signaling in tumors are already in clinical trials in humans to assess antitumor efficacy.
“Despite these caveats, therapies designed to interfere with HIF signaling in tumors are already in clinical trials in humans to assess antitumor efficacy [127].”
From Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function (2013) · cites this paper as [127]
The citation lists haven’t been fetched yet
References 206 · Cited by 41
- Authors
- Wilczynski, J., Duechler, M., & Czyz, M.
- Affiliations
- Centrum Badań Molekularnych i Makromolekularnych Polskiej Akademii Nauk (PL)
- ORCID
- Duechler, Markus
- Venue
- Archivum Immunologiae et Therapiae Experimentalis
- Publisher
- Walter de Gruyter GmbH
- Published
- 2011-05-28
- Volume
- 59
- Issue
- 4
- Pages
- 301-307
- ISSN
- 0004-069X (ISSN-L)
- 1661-4917
- OpenAlex
- W2000405060
- Cited by
- 41
- References
- 206
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 3 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 5 · 2016: 2 · 2015: 4 · 2014: 5 · 2013: 8 · 2012: 6
- FWCI
- 0.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Archivum Immunologiae et Therapiae Experimentalis (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and biological activity
- Keywords
- NF-κB, HIF-1, HIF-2, tumor hypoxia, solid tumors, chemoresistance, radioresistance (biology), HIF inhibitors, topotecan, Hsp90 inhibitors, mTOR inhibitors, YC-1, 2-methoxyestradiol, cancer therapy
- MeSH terms
- 2-Methoxyestradiol, Endothelial PAS Domain-Containing Protein 1, Animals, Antineoplastic Agents, Clinical Trials as Topic, Estradiol, Humans, Indazoles, Neoplasms, Transcription Factors, Tumor Cells, Cultured, Cell Hypoxia, NF-kappa B, Topotecan, Mice, Basic Helix-Loop-Helix Proteins, Hypoxia-Inducible Factor 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
